Epilepsy

Pyros Pharmaceuticals Announces Positive Outcome of the European Decentralised Procedure for Approval of VIGZIP™ (vigabatrin oral solution)

Retrieved on: 
Thursday, February 15, 2024

Pyros Pharmaceuticals, Inc. (Pyros or the Company), a leader in the development of enhanced specialty pharmaceuticals for rare diseases, announced today the positive outcome of the Decentralised Procedure (DCP) for VIGZIP™ (vigabatrin oral solution) in Europe.

Key Points: 
  • Pyros Pharmaceuticals, Inc. (Pyros or the Company), a leader in the development of enhanced specialty pharmaceuticals for rare diseases, announced today the positive outcome of the Decentralised Procedure (DCP) for VIGZIP™ (vigabatrin oral solution) in Europe.
  • "We are incredibly pleased with the positive outcome supporting the approval of VIGZIP™ in several key European markets.
  • This achievement serves as a testament to our dedication to developing innovative solutions for unmet medical needs in rare pediatric diseases.
  • Pyros remains committed to expanding access to VIGZIP™ in other additional territories around the world,” stated Michael Smith, Chief Executive Officer of Pyros.

ElleVet Academy Launches with Classes on Cannabinoid Veterinary Science, Offering Free RACE Approved CE Credits for Veterinary Professionals

Retrieved on: 
Thursday, February 15, 2024

PORTLAND, Maine, Feb. 15, 2024 /PRNewswire-PRWeb/ -- ElleVet Sciences, the leading authority on cannabinoid veterinary science, proudly announces the launch of ElleVet Academy (ellevetacademy.com), its online learning platform offering free continuing education (CE) credits to veterinary professionals. ElleVet Academy courses aim to empower veterinary professionals with the knowledge and skills needed to confidently incorporate cannabinoid-based products into their practice to support patients with osteoarthritis, epilepsy, atopic dermatitis, and anxiety.

Key Points: 
  • PORTLAND, Maine, Feb. 15, 2024 /PRNewswire-PRWeb/ -- ElleVet Sciences, the leading authority on cannabinoid veterinary science, proudly announces the launch of ElleVet Academy ( ellevetacademy.com ), its online learning platform offering free continuing education (CE) credits to veterinary professionals.
  • "ElleVet Academy represents a pivotal step in advancing veterinary education," said Dr. Joseph J. Wakshlag, Chief Veterinary Medical Officer, ElleVet Sciences.
  • Free Continuing Education Credits: Veterinary professionals can earn RACE-approved CE credits at no cost, making ElleVet Academy the most accessible and comprehensive resource for gaining essential education in cannabinoid veterinary science.
  • Scientific Expertise: ElleVet Academy courses were designed by the same veterinary professionals and researchers who brought cannabinoid veterinary science to the forefront of pet care.

Texas Original Opens New San Antonio Location, Launches Dark Chocolate Bites

Retrieved on: 
Wednesday, February 14, 2024

Texas Original , Texas’ leading medical cannabis provider, today announced the opening of its newest permanent prescription pickup location in San Antonio.

Key Points: 
  • Texas Original , Texas’ leading medical cannabis provider, today announced the opening of its newest permanent prescription pickup location in San Antonio.
  • Texas Original also announced the launch of its new Dark Chocolate Bites, the company’s first chocolate product and the state’s first medical cannabis chocolate product made with Rick Simpson Oil (RSO).
  • Like all Texas Original products, Dark Chocolate Bites are regulated and rigorously tested to ensure quality, consistency and purity.
  • The northeast San Antonio location is Texas Original’s third medical cannabis pickup location in the San Antonio area, joining the company’s existing locations in west San Antonio and Universal City.

Recognizing when someone is having a seizure – and how you can help during those first critical moments

Retrieved on: 
Wednesday, February 14, 2024

But experiencing a seizure does not always mean a person has epilepsy.

Key Points: 
  • But experiencing a seizure does not always mean a person has epilepsy.
  • Seizures can be provoked by acute head injuries, alcohol withdrawal and high blood sugar, among other things.

What does a seizure look like?

  • For some people, their seizure is a purely internal sensation.
  • In fact, most people with epilepsy have only relatively subtle, nonconvulsive seizures at first, then develop convulsive seizures over time.
  • This is the type of seizure most of us are familiar with, probably because it’s the kind most frequently depicted, though not always accurately, in movies and on television.
  • The most common type of epileptic seizure are those that are focal – that is, they arise from a confined region of the brain.

What causes a seizure to occur?


Seizures are the result of abnormal electrical activity in the brain. The bursts of activity disrupt normal functioning and initiate hyperactivity in the affected brain area, which then can affect the corresponding body part. For instance, if the seizure arises from the part of the brain involved in arm movement, that arm will experience involuntary hyperactivity.

If you’re a bystander, how can you help?

  • Many seizure-related injuries occur due to falling or coming in contact with sharp or hard objects.
  • If they begin to fall, help them to the floor as gently as possible and put something soft under their head.
  • During the convulsive phase of a seizure, breathing may be intermittent.
  • So turn the person on their side so they can breathe more easily and lower the risk of aspiration.
  • Following the seizure, and as the person gradually recovers and wakes up, help them sit up in a safe space.

Are new treatments available?

  • People with epilepsy, particularly those who experience frequent seizures, will often have emergency medications in their possession.
  • The most common emergency medications – also called seizure rescue medications – are a type of anticonvulsants called benzodiazepines.
  • Patients and their caretakers may have access to rescue medications and know how to use them.

What if it’s not a seizure?


If a bystander does not witness a seizure, but instead finds someone unresponsive or minimally responsive, call 911. They may be suffering from other medical issues, such as a drug overdose. And if you are interested in training and certification for seizure first aid, or if you simply want to know more, the Epilepsy Foundation has more information.

  • Jacob Pellinen has received research support from the Department of Neurology at the University of Colorado School of Medicine, the Colorado Clinical and Translational Sciences Institute, NIH/NINDS, and the American Epilepsy Society.
  • J. Pellinen serves as chair of the professional advisory board for the Epilepsy Foundation of Colorado and Wyoming (unpaid), serves as the Epilepsy Section Editor for Current Neurology and Neuroscience Reports, and has received compensation for serving on the scientific advisory board for SK Life Science.

ZyVersa Therapeutics Highlights Review Article Substantiating That Inflammasome Activation Is Pathogenic in Multiple Neurological Diseases

Retrieved on: 
Wednesday, February 14, 2024

The review article summarizes data demonstrating that inflammation resulting from activation of more than one type of inflammasome contributes to development of neurological diseases and that ASC specks lead to their progression.

Key Points: 
  • The review article summarizes data demonstrating that inflammation resulting from activation of more than one type of inflammasome contributes to development of neurological diseases and that ASC specks lead to their progression.
  • ZyVersa is developing IC 100, a monoclonal antibody targeting inflammasome ASC and ASC specks from multiple types of inflammasomes to block initiation and perpetuation of damaging inflammation.
  • (Nasdaq: ZVSA or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, highlights data from a review article published in Nature Reviews Neurology.
  • The authors concluded, “Use of inflammasome-targeted therapeutic approaches could improve existing therapeutic strategies for multiple neurological conditions.” To review the publication, Click Here .

RespireRx Pharmaceuticals Inc. Reports Preclinical Pain Relief for their Non-Opioid Lead GABAkine

Retrieved on: 
Tuesday, February 13, 2024

Launched in April 2018, the initiative is focused on improving prevention and treatment strategies for opioid misuse and addiction, and enhancing pain management.

Key Points: 
  • Launched in April 2018, the initiative is focused on improving prevention and treatment strategies for opioid misuse and addiction, and enhancing pain management.
  • The PSPP program, part of the NIH HEAL Initiative, evaluates non-opioid assets in a battery of established preclinical pain models.
  • These observations were made with both male and female rats in two measures each, in models of post-incision pain and spinal nerve ligation-induced persistent neuropathic pain.
  • These data trigger the advancement of KRM-II-81 within the NIH PSPP program where additional disease-specific pain models will be evaluated.

Stratus Announces Full-Service Remote Continuous EEG Monitoring for Hospitals

Retrieved on: 
Monday, February 12, 2024

IRVING, Texas, Feb. 12, 2024 /PRNewswire-PRWeb/ -- Stratus, the nation's leading provider of electroencephalogram (EEG) testing, announced the nationwide expansion of its remote EEG monitoring services for the intensive care unit (ICU) setting at the Critical Care Congress in Phoenix, AZ this month. Continuous monitoring of EEG recording for a subset of patients in the ICU can lead to improved outcomes for the patient and reduced length of stay in the ICU.

Key Points: 
  • Stratus' nationwide expansion of remote EEG monitoring services for hospitals was launched at the 2024 Critical Care Congress.
  • IRVING, Texas, Feb. 12, 2024 /PRNewswire-PRWeb/ -- Stratus, the nation's leading provider of electroencephalogram (EEG) testing, announced the nationwide expansion of its remote EEG monitoring services for the intensive care unit (ICU) setting at the Critical Care Congress in Phoenix, AZ this month.
  • Continuous EEG monitoring can be a vital part of care for certain patients admitted to the ICU.
  • Stratus' remote monitoring services provide registered and highly skilled EEG technologists who can monitor the EEG recordings of patients 24 hours a day, 365 days per year.

Cord Blood Registry® (CBR®) by CooperSurgical® and Fulgent Genetics Launch Innovative Genetic Testing

Retrieved on: 
Friday, February 9, 2024

‍TRUMBULL, Conn. and EL MONTE, Calif., Feb. 9, 2024 /PRNewswire/ -- CooperSurgical®, a global leader in fertility and women's health, and Fulgent Genetics, Inc. (NASDAQ: FLGT), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced that they have partnered to offer families of Cord Blood Registry® (CBR®) exclusive newborn genetic screening panels.

Key Points: 
  • CBR Portrait includes more than twice as many genes as CBR Snapshot and may identify more rare causes of these conditions.
  • CBR Landscape also includes a pharmacogenetic (PGx) component, which is a type of genetic testing that can determine how a person breaks down or metabolizes certain medications.
  • "Part of our mission is to use our resources and testing to improve the lives of those around us.
  • Newborn genetic analysis serves as an illustration of this commitment, as early intervention may significantly improve health outcomes for many of these conditions."

Seizure Action Plan Awareness Week Set For February 12-19

Retrieved on: 
Wednesday, February 7, 2024

BATON ROUGE, La., Feb. 7, 2024 /PRNewswire/ -- The Seizure Action Plan Coalition , a collaboration managed by Epilepsy Alliance America , will hold the 4th Annual Seizure Action Plan (SAP) Awareness Week Feb. 12-19, 2024.

Key Points: 
  • BATON ROUGE, La., Feb. 7, 2024 /PRNewswire/ -- The Seizure Action Plan Coalition , a collaboration managed by Epilepsy Alliance America , will hold the 4th Annual Seizure Action Plan (SAP) Awareness Week Feb. 12-19, 2024.
  • Let's unite to raise awareness during Seizure Action Plan Awareness Week," said Brad Chapman, Head of U.S. Epilepsy and Rare Syndromes.
  • The Seizure Action Plan Coalition website has tools and resources from its awareness partners for individuals with epilepsy and their families.
  • For more information on Seizure Action Plan Awareness Week, visit SeizureActionPlans.org today.

Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Retrieved on: 
Tuesday, February 6, 2024

NEW YORK, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that management will participate in a virtual presentation at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13, 2024, at 12:40 p.m.

Key Points: 
  • NEW YORK, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that management will participate in a virtual presentation at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13, 2024, at 12:40 p.m.
  • ET.
  • A live webcast of the Oppenheimer presentation can be accessed through the Events & Presentations section of the Company’s website at investors.ovidrx.com .
  • An archived replay of the webcast will be available on the Company’s website following the live presentation for approximately 90 days.